I-131 therapy for thyroid cancer with recombinant human thyroid-stimulating hormone (Thyrogen)

I-131 therapy for thyroid cancer with recombinant human thyroid-stimulating hormone (Thyrogen) - I-131 therapy for thyroid cancer with recombinant human thyroid-stimulating hormone

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005692

Enrollment

Registered

2011-06-01

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid cancer

Interventions

recombinant human thyroid-stimulating hormone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) a patient who underwent total thyroidectomy for thyroid cancer 2) a patient with distant metastases of thyroid cancer 3) a patient whose endogenous thyroid-stimulating hormone can not be secreted because of pituitary surgery

Exclusion criteria

Exclusion criteria: 1) pregnant female and feeding female 2) a patient with disturbed consciousness 3) expected life interval less than 1 month 4) risks for the central nerve system during treatment 5) when medical staff determine that treatment can not be properly carried out

Design outcomes

Primary

Measure	Time frame
Assessment of anti-tumor effects with tumor size and tumor markers	—

Secondary

Measure	Time frame
Assessment of harmful effects in bone marrow, digestive organ, and salivary gland	—

Countries

Japan

Contacts

Public ContactDaiki Kayano

Kanazawa University Hospital Department of Nuclear Medicine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026